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Background: Despite hospitalization for exacerbation being a high-risk event for morbidity 
and mortality, there is little consensus globally regarding the assessment and management of 
hospitalised exacerbations of COPD. We aimed to establish a consensus list of symptoms, 
physiological measures, clinical scores, patient questionnaires and investigations to be 
obtained at time of hospitalised COPD exacerbation and follow-up.
Methods: A modified Delphi online survey with pre-defined consensus of importance, 
feasibility and frequency of measures at hospitalisation and follow-up of a COPD exacerba-
tion was undertaken.
Findings: A total of 25 COPD experts from 18 countries contributed to all 3 rounds of the 
survey. Experts agreed that a detailed history and examination were needed. Experts also 
agreed on which treatments are needed and how soon these should be delivered. Experts 
recommended that a full blood count, renal function, C-reactive protein and cardiac blood 
biomarkers (BNP and troponin) should be measured within 4 hours of admission and that the 
modified Medical Research Council dyspnoea scale (mMRC) and COPD assessment test 
(CAT) should be performed at time of exacerbation and follow-up. Experts encouraged 
COPD clinicians to strongly consider discussing palliative care, if indicated, at time of 
hospitalisation.
Interpretation: This Europe-wide consensus document is the first attempt to standardise 
the assessment and care of patients hospitalised for COPD exacerbations. This should be 
regarded as the starting point to build knowledge and evidence on patients hospitalised for 
COPD exacerbations.
Keywords: COPD, disease exacerbation, hospitalisation, patient care, consensus 
development, expert opinion
Introduction
Hospitalised exacerbations of chronic obstructive pulmonary disease (COPD) 
account for a significant proportion of bed pressures and hospital costs throughout 
the world, including Europe1,2 and North America.3 These exacerbations also 
confer a high risk of in-hospital mortality of approximately 5–8%4,5 and carry up 
to 58% risk of re-admissions within 1 month6,7 and up to a 20–25%5 risk of 
mortality in the 12 months following discharge.
Major international COPD guidelines8,9 provide clinicians with very little gui-
dance for standardisation of clinical assessment, examination, laboratory and radi-
ological tests and treatment in hospitalised exacerbations of COPD (HECOPD). 
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There is also no consensus on patient follow-up frequency 
and the details on what should be measured during the post 
hospitalisation follow-up phase. For example, the Global 
Initiative for Chronic Obstructive Lung Disease (GOLD) 
suggests measuring spirometry in everyone hospitalised 
for an exacerbation of COPD.8 A 2016 European audit4 
showed that more than half of patients admitted to hospital 
for an exacerbation of COPD had never had a spirometry 
recorded. Similarly, the GOLD report8 recommends the 
measurement of an arterial blood gas, yet uptake of this 
is incomplete.4 Even in long-term treatment decisions, 
such as the use of long-term oral corticosteroids, physician 
practices do not match the guidelines.10
Our colleagues in other fields of acute hospital care, 
such as cardiology and rheumatology, have enviable evi-
dence-based guidelines.11,12 These often define what, 
when, how and the frequency a patient should have 
assessment of symptoms, tests, outcomes and treatments. 
This has led to standardisation of treatment protocols and 
clinical trial endpoints. Without a doubt, this has played 
a major contributory role in the improvements in patient 
outcomes in rheumatoid arthritis13 and myocardial 
disease.14 There are also clear lessons that COPD specia-
lists can take on board from other clinical areas. In 
2004,15 the Outcome Measures in Rheumatology 
(OMERACT) collaborative set out to achieve an expert 
consensus statement on different outcome measures and 
treatment goals in caring for patients with psoriatic arthri-
tis. Like for HECOPD, they set out from a place of 
limited evidence and aimed to achieve a standardised 
starting point to then build their evidence base on. 
Within a few years, the collaborative achieved global 
expert consensus on outcomes in psoriatic arthritis 
care,16 which was then taken up by major international 
professional bodies.17
With this context, we have investigated consensus as 
well as the areas of disagreement in the evaluation of the 
expert view on demographic, clinical characteristics, 
comorbidities, investigations and clinical outcomes for 
patients who are hospitalised for acute exacerbations of 
COPD as part of the CICERO collaboration.18
Methods
This study used a modified, 3-round online survey based 
on the Delphi method19 to establish a defined list of vari-
ables that should be measured at the time of a HECOPD. 
The survey was conducted via a secure online survey 
platform (surveymonkey.com). The variables were divided 
into symptoms, examination findings, co-morbidities, clin-
ical scores, laboratory tests, point of care test (eg, ECG, 
spirometry), other tests (eg, radiology, detailed lung func-
tion tests), treatments and clinical outcomes of importance. 
All the items were assessed for use at time of hospitalisa-
tion and at the post hospitalisation follow-up phase. 
Excepting the history-taking sections, the feasibility of 
undertaking each of these assessments and treatments 
was also assessed. Ethics or institutional review board 
approval was not required. This survey was exempt from 
approval as it was non-invasive, undertaken voluntarily by 
medical professionals and did not involve any patients.
Expert Selection
To understand current practice in Europe and to derive 
a consensus list of variables, we set out to invite 
a diverse panel of COPD experts from as many countries 
in Europe as possible. Policy Delphi20 methodologists 
recommend a panel size of between 15–40 experts to 
achieve an appropriate balance between points of view. 
Experts were contacted by the European Respiratory 
Society if they met 2 or more of the following criteria:
1. Board-certified pulmonologists who currently spend 
at least 20% of their time caring for patients hospi-
talised for acute exacerbation of COPD
2. Evidence of publication of important COPD 
research relevant to assessment or management of 
patients hospitalised for exacerbations of COPD
3. A history of participation in the development of 
local or national guidelines for the management of 
COPD
Delphi Process
The modified Delphi process consisted of 3 iterative 
rounds (subsequently called rounds 1, 2 and 3). Each 
expert was provided a unique secure link to an online 
questionnaire platform. The variables were listed in 
groups, and experts were asked to rate the importance, 
feasibility and a suggested frequency on a Likert scale. 
Experts were reminded that the survey sought to obtain 
their opinion on clinical care for HECOPD. Free text 
capability for expert comments were sought for each sec-
tion. Any new item suggested was added to the following 
round of the electronic survey. Members then returned the 
completed online surveys anonymously. Experts were 
asked to return surveys within a 3-week period. 
Reminder e-mails were sent to encourage completion, 
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and extensions were given when necessary. This is sum-
marised in Figure 1.
Consensus, dissensus and stability criteria for the 
Delphi process were pre-determined prior to Delphi pro-
cess commencement. Consensus21,22 was defined as an 
interquartile range (IQR) of ≤1 for a 4- or 5-point Likert 
scale item. For 3-point Likert scales and for Yes/No items, 
an IQR of 0 was needed to achieve consensus. A Wilcoxon 
signed rank test was performed on paired results of 
expert’s responses to assess stability of responses between 
rounds. If the responses were not statistically significantly 
different (p value ≥ 0.05), responses were considered 
stable. At the completion, any item that reached a score 
of “important“, “important to very important“ or “very 
important“ was included in the final consensus list. The 
corresponding feasibility and frequency were also reported 
Figure 1 Schematic illustrating the Delphi survey process.
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if consensus was achieved. If items were rated “neutral“ or 
“neutral to important“, they were assigned as “to be con-
sidered” in any future evaluation. Items where consensus 
was not achieved are also reported.
Variable Selection
A detailed literature review was undertaken by SR and MB 
to assess the current evidence basis for symptoms, exam-
ination findings, co-morbidities, clinical scores, laboratory 
tests, point of care test (eg, electrocardiogram, spirometry), 
other test (radiology, detailed lung function tests), treat-
ments and clinical outcomes of importance for use in hos-
pitalised patients with exacerbation of COPD (search 
criteria used are available in supplementary Table 1), prior 
to design of the Delphi survey. A final decision for survey 
input was made at a face to face meeting by SR, MB, WJ 
and AH.
Round 1
As we were aiming to establish experts’ views on many 
variables and many aspects of the variable (importance, 
frequency, feasibility etc), a skip logic was programmed to 
help reduce the survey burden. If an expert marked a variable 
as “Not at all important” on the importance Likert scale, the 
item was removed from the survey for that expert for all 
subsequent lower order items (eg, feasibility). In other words, 
if experts rated something as not important, then aspects of 
that item, eg, feasibility and frequency, were deemed irrele-
vant for the remainder of round 1.
Round 2
All items that achieved consensus in round 1 were 
removed from round 2. If consensus was only achieved 
on one aspect of the item, for example the importance of 
a particular clinical test, but not the feasibility or fre-
quency, the importance section was not re-evaluated in 
round 2, but the other aspects were re-evaluated. Any 
variable that was re-evaluated was accompanied by 
a histogram of the previous round’s expert responses and 
a median of the responses. Any items suggested by experts 
in round 1 were also included in round 2. No skip logic 
was programmed for round 2.
Round 3
Again, variables achieving consensus were removed. For 
items that did not achieve consensus, stability was 
assessed. If a variable remained in dissensus and 
remained stable, the item was removed and marked as 
“stable disagreement”. If a variable remained in dissen-
sus but had changed significantly, the item was marked 
for re-evaluation in round 3. Like round 2, any new 
suggestions from experts in round 2 were included. 
Questions were modified for clarity and/or specificity 
in response to experts’ suggestions. There was no skip 
logic. Any variable that was re-evaluated was accompa-
nied by a histogram of the previous round’s expert 
responses and a median of the responses for both 
rounds.
Results
A total of 25 COPD experts from 19 European countries 
completed all 3 rounds of the Delphi survey. There were 
3 experts from the UK; 2 each from the Netherlands, 
France, Germany and Italy; and 1 each from Belgium, 
Spain, Switzerland, Portugal, Croatia, Estonia, Serbia, 
Latvia, Sweden, Turkey, Slovenia, Finland, Greece and 
Poland. There were 8 (32%) female experts, and the 
majority were aged between 41–50 years (56%). All 
experts worked in the field of COPD in secondary or 
tertiary/academic institutions. On average, experts spent 
22% of their time caring for respiratory inpatients. All 
but one of the experts were actively involved with 
research into COPD care. After round 2, no further 
new items were recommended to gain consensus. The 
survey was sent and completed prior to the coronavirus 
disease 2019 (COVID-19) pandemic.
Expert Consensus Opinion During an 
Acute Hospitalised Exacerbation of 
COPD
Symptoms
There were 29 symptoms that were assessed for impor-
tance, method of symptom data capture (binary vs severity 
scale) and frequency of symptom capture. After 3 rounds, 
no consensus was achieved on 3 items (low mood, sneez-
ing and poor sleep). A further 2 symptoms, namely runny 
eyes and itchiness, were excluded by experts. Of the 
remaining 24 symptoms, experts recommend that 12 
symptoms must be recorded at time of exacerbations and 
12 that ought to be considered (see Table 1). The experts 
endorse that most symptoms could be recorded in a binary 
form (ie, present or absent). For the symptoms of cough 
and sputum purulence respectively, experts could not agree 
whether this should be reported quantitively (on a scale of 
severity) or qualitatively (absent or present) after 3 rounds.
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Co-Morbidities
Respondents recommended that a complete and detailed med-
ical history was necessary at time of exacerbation. Some 
medical history items, namely, history of atopy, osteoporosis, 
chronic kidney disease, human immunodeficiency virus (HIV) 
status and non-lung primary malignancy were rated as being 
less important for routine recording but should be considered.
Clinical Signs
Consensus was achieved on the importance of recording 
respiratory clinical signs. However, expert opinion was 
that treating physicians need only consider recording 
some cardiac signs, such as heart murmurs, pulsus para-
doxus, jugular venous pressure (JVP), in addition to body 
weight at time of hospitalised exacerbations (see Table 2). 
Experts agreed that menstrual cycle, forearm and quadri-
ceps strength, abdominal distension, abdominal tenderness 
and pulsatile liver edge did not need to be actively 
recorded unless relevant to the patient history. The con-
sensus list of clinical signs to elicit at the post hospitalisa-
tion follow-up phase are listed in supplementary Table 2.
Clinical Tests
An expert consensus was reached on which tests should 
be performed at the time of a severe hospitalised exacer-
bation of COPD (see Table 3). Experts recommend that 
a full blood count, renal function, C-reactive protein 
(CRP), cardiac troponin and BNP are essential tests and 
should be completed within 4 hours of hospitalisation. 
Similar to this, the experts recommended that a chest 
radiograph and ECG should be performed as soon as 
possible. The optimum timing of when other essential 
tests should be performed (namely arterial blood gas, 
sputum cultures and viral swabs) could not be decided. 
Other routinely available tests were recommended by 
experts to be investigations to consider, reflecting on 
occasion the healthcare system available to experts. This 
included common tests such as lactate dehydrogenase 
(LDH) and nasopharyngeal swab for non-influenza 
respiratory viruses. Tests not included in the consensus 
recommendation are listed in supplementary Table 3. 
Experts could not agree on the importance of performing 
any point of care assessment of lung function or inflam-
mation at time of acute exacerbation (including peak flow, 
spirometry and exhaled nitric oxide). All tests at the post 
hospitalisation follow-up phase that were recommended 
for consideration and excluded by expert consensus are 
listed in supplementary Table 3.
Clinical Scores and Questionnaires
A wide range of related clinical severity scores and ques-
tionnaires were assessed for their utility and feasibility (see 
supplementary Table 4). Experts felt that only 3 should be 
done at time of hospitalised exacerbation; these were the 
modified Medical Research Council (mMRC) dyspnoea 
scale, the COPD assessment test (CAT) and asking about 
frequency of exacerbations (frequent exacerbator pheno-
type) (see Table 4). The majority of clinical scores/question-
naires were excluded by consensus (see supplementary 
Table 1 Recommended Symptom Data Capture at Time of 
Hospitalised Exacerbation
Must Be Recorded
Symptoms How to Measure Frequency
Dyspnoea Severity scale Daily
Wheeze Binary Daily
Increased sputum volume Binary Daily
Sputum purulence No consensus achieved Daily
Cough No consensus achieved Daily
Fever Binary Twice a day to daily
Use of rescue medication Severity scale Daily
Increased inhaler use Binary Daily
Reduced exercise tolerance Severity scale Daily to once in admission
Confusion Binary Daily
Loss of consciousness Binary Daily
Orthopnoea Binary Daily to once in admission
Consider Recording
Chest tightness Binary Daily
Chest pain Binary Daily
Haemoptysis Binary Daily




Poor appetite Binary Daily
Palpitations Binary Daily
Sore throat Binary Daily
Runny nose Binary Daily
Headache Binary Daily
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Table 5), including the SGRQ, APACHE and EXACT-Pro. 
These recommendations also extended to the post hospitali-
sation follow-up phase (see supplementary Table 5).
Pharmacological Treatments (When Indicated)
Expert opinions related to treatments, when clinically indi-
cated, achieved the greatest amount of consensus early in the 
Delphi, including the treatments that need to be given and 
when they should be commenced (see Table 5). When clini-
cally indicated, experts recommended that patients hospita-
lised with an exacerbation of COPD be treated with systemic 
corticosteroids and antibiotics, for 5 to 7 days in total, with 
systemic corticosteroids dosing equivalent to 30–50 mg of 
prednisolone daily. Experts recommended that nebulised 
therapy duration should be given for a maximum of 5 days, 
although there was a greater variation of opinion on duration. 
Experts strongly recommended that long-term inhaler opti-
misation should be performed prior to discharge.
Non-Pharmacological Treatments
Experts expected smoking cessation advice to be provided at 
every hospitalisation, in addition to seeing a respiratory phy-
siotherapist. A referral to pulmonary rehab was considered 
a routine requirement. Although ideal, seeing a COPD specialist 
nurse at every hospitalisation was not deemed feasible. Experts 
also recommend that it was very important and very feasible to 
discuss palliative care, goals of care, symptom control and 
resuscitation status at every hospitalised exacerbation.
Outcomes at the Post Hospitalisation Follow-Up 
Phase
The consensus opinion among experts was that patients 
should only be considered stable at 6 weeks (median, 
IQR 6 to 12 weeks) post hospitalisation for COPD 
exacerbation. Experts were also able to make recommen-
dations on the list of outcomes that should be used to 
define “treatment failure”, both in clinical practice and in 
research (see Table 6).
Potential Controversies
Experts recommended that an echocardiogram should be part 
of clinical care for patients with a hospitalised exacerbation 
of COPD following round 3; however, no consensus was 
reached as to when this should be performed (ie, in hospital 
or after discharge) or whether this should be performed 
routinely or only if clinically indicated. Computed tomogra-
phy (CT) scans of the thorax and peak flow measurements 
led to strongly conflicting opinions of experts saying it was 
Table 2 Recommended Clinical Signs Data Capture at Time of Hospitalised Exacerbation
Clinical Signs Inclusion Frequency
Blood oxygen saturation Must At least once every 4 to 12 hours
Supplemental oxygen amount Must At least once every 12 hours
Heart rate Must At least once every 12 hours
Respiratory rate Must At least once every 12 to 24 hours
Use of accessory respiratory muscles Must At least once every 12 to 24 hours
Change in mental state Must At least once every 12 to 24 hours
Blood pressure Must At least once every 12 to 24 hours
Temperature Must At least once every 12 to 24 hours
Wheeze on assessment/examination Must At least once every 12 to 24 hours
Irregular pulse Must At least once every 12 to 24 hours
Silent chest Must At least once every 12 to 24 hours
Orthopnoea Must At least once every 12 to 24 hours
Crackles Must At least once a day
Ronchi Must At least once a day
Pursed lip breathing Must At least once a day
Ankle oedema Must At least once a day
Presence of raised JVP Must At least once a day
Colour of sputum Must At least once a day
Body mass index Must Once during admission
Degree of raised JVP Consider Once a day to once during admission
Heart murmurs Consider Once a day to once during admission
Hoover’s sign Consider Once a day to once during admission
Weight Consider Once a day to once during admission
Pulsus paradoxus Consider Once a day to once during admission
Abbreviation: JVP, jugular venous pressure.
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either “not at all important” or “very important”, and these 
polarised opinions were not resolved after 3 rounds.
Discussion
We report here the expert consensus recommendations from 
a detailed Delphi study in standardisation of measurements in 
the management of patients with HECOPD. These included 
symptoms, examination findings, co-morbidities, clinical 
scores, laboratory tests, point of care tests and treatments.
This is the first proposal of standardised data collection in 
clinical practice for severe hospitalised exacerbations of 
COPD (see https://www.cicero-copd.net/ for hospital 
Table 3 Recommended Tests to Perform at Time of Hospitalised Exacerbation of COPD
Tests Inclusion Within 4 Hours Within 8 Hours Within 12 Hours Within 24 Hours Within Admission
Full blood count Must ✓




Glucose Must No consensus achieved on time to first test
Liver function tests Must No consensus achieved on time to first test
ABG Must No consensus achieved on time to first test
Chest X-ray Must As soon as possible during admission
Electrocardiogram Must As soon as possible during admission
Echocardiogram Must No consensus achieved on time to first test
Sputum MCS Must No consensus achieved on time to first test
Influenza viral throat swab Must No consensus achieved on time to first test
6-minute walk test Must No consensus achieved on time to first test
Lactate dehydrogenase Consider No consensus achieved on time to first test
High-sensitivity CRP Consider No consensus achieved on time to first test
Procalcitonin Consider No consensus achieved on time to first test
Urine dipstick Consider No consensus achieved on time to first test
Viral throat swab Consider No consensus achieved on time to first test
CT scan of thorax Consider No consensus achieved on time to first test
Grip strength Consider No consensus achieved on time to first test
Quadricep strength Consider No consensus achieved on time to first test
Overnight oximetry Consider No consensus achieved on time to first test
Abbreviations: BNP, brain natriuretic peptide; CRP, C-reactive protein; ABG, arterial blood gas; MCS, microscopy, culture and sensitivities; DLCO, diffusing capacity of lung 
for carbon monoxide; CT, computed tomography.
Table 4 Recommended Clinical Scores and Questionnaires to Be Taken at Time of Hospitalised Exacerbation
Clinical Score/Questionnaires Inclusion Frequency
mMRC dyspnoea index Must At the start and end of admission
COPD assessment test Must At the start and end of admission
Frequent exacerbator phenotype Must Once during admission
BODEx Consider Once during admission
CURB-65 Consider Once during admission
Glasgow Coma Scale Consider Once during admission
GOLD I–IV Consider Once during admission
GOLD A–D Consider Once during admission
Visual analogue scale for symptoms Consider At the start and end of admission
Early warning chart* Consider Daily
HADS* Consider Once during admission
DECAF* Consider Once during admission
Clinical COPD questionnaire* Consider No consensus achieved
Notes: *European experts felt that these scores may not be feasible in some centres. References for clinical scores and questionnaires listed in Supplementary Table 4. 
Abbreviations: mMRC, modified Medical Research Council; BODEx, body mass index, degree of airflow obstruction, dyspnoea, exacerbations; CURB-65, confusion, urea, 
respiratory rate, blood pressure, age >65; GOLD, global initiative for chronic obstructive lung disease; HADS, hospital anxiety and depression scale; DECAF, dyspnoea, 
eosinopenia, consolidation, acidemia and atrial fibrillation.
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exacerbation standardisation tool). This Delphi survey is 
a robust method to obtain consensus on standardisation of 
many aspects of hospitalised COPD management and pro-
vides a real-life perspective on the components prioritised by 
COPD physicians. The experts selected represent COPD 
physicians from across Europe with diverse health systems. 
We believe our high retention rate of experts throughout the 
three survey rounds is indicative of the importance of gaining 
standardisation for hospitalised exacerbation management, in 
addition to certain features of programming such as skip 
logics which ultimately reduced participant “click” burden. 
We found that, overall, there was a great deal of consensus 
amongst COPD experts. We specifically assessed importance 
and feasibility separately to establish an ideal set of mea-
sures; this assessment of a clinician's opinion on importance 
and how feasible a measure is has not been made before.8 We 
also pre-defined consensus and stability criteria prior to study 
commencement to prevent post hoc adjustments to affect 
inclusion threshold.22 We found very few occasions where 
an item (eg, a question in the survey) was found to be rated 
important and regarded as not feasible simultaneously.
As expected, all experts agreed that a detailed medical 
history and physical exam were important at time of 
hospitalisation, as per current recommendations.8 
However, the inability of experts to agree on how to 
measure two very common symptoms, such as cough 
and sputum purulence, clearly exemplifies the need to 
urgently standardise recording of these symptoms. Our 
effort will almost certainly aid clinical practice, research 
practice and consequently patient outcomes. Furthermore, 
it is recognised that cardiovascular disease is a substantial 
cause of morbidity and mortality in patients with 
COPD;23 however, the expert opinion in our survey pre-
dominantly graded respiratory physical signs of higher 
importance than cardiac signs. This may reflect bias in 
asking respiratory experts or that simply assessing cardiac 
Table 5 Recommendations Regarding Treatment Allocation, if Indicated, at the Time of Hospitalised Exacerbation of COPD
Treatment Within 30 Minutes Within 60 Minutes Within 4 Hours Within 24 Hours
Oxygen ✓
Nebulised short-acting beta agonists ✓









Table 6 Recommended Treatment Failure Assessments at 30 Days After Hospitalised Exacerbation of COPD
Treatment Failure Outcome to Assess Inclusion
Mortality Must
Intensive care admission requirement Must
Re-admission Must
Re-treatment with steroids and/or antibiotics for COPD exacerbation Must
Health care utilisation (any of hospital presentation, primary care or urgent care visit) Must
Length of stay Must
New or worsening co-morbidities following the index exacerbation event (eg, diabetes, osteoporosis) Must
Increase in short-acting inhaled therapy Must
Cumulative use of systemic steroids Must
Change in symptom scores Consider
Quality of life scores Consider
submit your manuscript | www.dovepress.com                                                                                                                                                                                                                    
DovePress                                                                                            
International Journal of Chronic Obstructive Pulmonary Disease 2021:16 328

















































































Powered by TCPDF (www.tcpdf.org)
signs alone is insufficient to address cardiovascular risk. 
Moreover, it is worth noting that our experts recommend 
that cardiac biomarkers such as BNP, troponin, ECG and 
echocardiogram are essential tests in the management of 
a patient hospitalised with an exacerbation, and in the 
case of BNP, troponin and an ECG these should be 
performed within 4 hours (or as early as possible) of 
the admission. This recommendation highlights the 
importance of assessing cardiovascular risk in patients 
with COPD, where mortality is high.23 It is recognised 
that there is an increased risk of cardiovascular events 
within 30 days of hospitalisation for an exacerbation of 
COPD24 and that it is highly likely that clinical or sub- 
clinical cardiovascular disease may worsen during 
a severe exacerbation.
The experts’ views on blood, radiology and assess-
ments of lung function at the time of hospitalised COPD 
exacerbation were interesting. Unlike asthma guidelines, 
current COPD guidelines do not recommend point of care 
lung function testing during an exacerbation.8,9 This was 
also reflected by our experts not agreeing on any point of 
care test (including peak flow) and thus not recommending 
this as an investigation at time of hospitalisation. This 
could reflect the limitations with spirometry or peak flow 
as an available tool25 and the lack of evidence to suggest it 
alters clinical management at the time of an exacerbation. 
This contrasts with the expert consensus regarding the 
value of spirometry at time of follow-up, as a diagnostic 
requirement. It is conceivable, however, that other more 
sensitive tools assessing airway obstruction, such as 
impulse oscillometry testing,26 need to be considered at 
time of hospitalisation or follow-up.
In contrast to this, there was expert consensus and 
recommendation that full blood count, renal function and 
CRP should be performed within 4 hours of an admission. 
The use of the peripheral blood eosinophil count27 and 
serum C-reactive protein28 during a HECOPD is still being 
evaluated. Meanwhile, although other tests were consid-
ered to be important, there was no consensus as to when 
these should be performed. We believe that the variability 
in the severity of HECOPD could impact on timeline 
decision-making and is thus reflected as dissensus in this 
survey.
The experts recommended that a chest radiograph 
should be performed as soon as possible within the admis-
sion. This is in line with current recommendations. Chest 
X-ray is used frequently29–31 despite evidence showing 
that it rarely alters30 clinical management. Research on 
the value of a CT of the chest during HECOPD is 
ongoing;32 whilst the relative infeasibility of CT scans 
likely contributed to strongly polarised views on its impor-
tance at time of HECOPD.
Finally, experts agreed that only the mMRC33 and the 
CAT34 must be assessed at time of hospitalisation. Despite 
there being a wide variety of risk tools to assess COPD 
exacerbation and mortality risk, external validation of 
these risk tools at the time of a hospital admission is 
limited35 and is likely to have attributed to expert opinion 
on which risk tools/scores are required at the time of 
a hospitalisation of COPD.
Following this expert consensus, we have defined 
a patient to be stable following a hospitalisation of 
COPD at 6 weeks, with a range of timepoints from 6 to 
12 weeks to define stability, after hospitalisation. We 
believe it is of great importance that our experts were 
able to provide opinion on how to define a treatment fail-
ure. Our experts recommended that a treatment failure 
outcome should be measured at 30 days; in addition to 
currently approved definitions (of death or re-treatment for 
example), we should also capture outcomes related to 
cumulative systemic corticosteroid use, use of short- 
acting inhaler use and new or worsening of concomitant 
co-morbidities. These additional components seek to 
address harm of treatment, where the evidence is now 
increasing.36
There are several limitations to discuss. Firstly, it is 
important to note that the consensus decisions derived 
from this survey reflect expert opinion, and there is little 
evidence supporting the practice of measuring these out-
comes at time of hospitalisation for an exacerbation of 
COPD. However, due to the paucity of evidence or best 
practice, this is where the Delphi method works best. In 
particular, this Delphi approach in management of hospi-
talised COPD exacerbations can serve to act as 
a springboard to start standardising, building evidence 
and importantly to improve care. We feel that COPD 
physicians should not accept the status quo simply because 
there is no evidence to guide change. Secondly, as 
expected,19 an expert-led Delphi process would favour 
more detail and intervention than that which is potentially 
plausible in day to day practice. To resolve this, we spe-
cifically asked about the feasibility of all items, especially 
considering local costs, and practice limitations. All the 
items proposed reached a rating of “feasible to very fea-
sible“. We believe that our success at bringing together 
a broad expert panel from across Europe makes this 
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document workable in clinical practice across Europe. 
This has led to recommendations of symptoms, signs, 
tests and outcomes which are all eminently feasible. 
A further limitation is that our experts were pre-selected 
pulmonologists practising in Europe. This may potentially 
make our results difficult to generalise to low- and middle- 
income countries; however, we feel this limitation will 
only apply to the selection of investigations at the time 
of a hospitalised exacerbation. The exclusion of allied 
health professionals from the expert panel could also 
limit the generalisability/acceptability of the proposed 
standardisation consensus. As part of the CICERO clinical 
research collaborative, we are now seeking patients' views 
on our expert consensus through a multi-national, multi- 
lingual survey, run in collaboration with the European 
Lung Foundation. This standardisation is also being 
piloted in a Europe-wide cohort study of 1000 hospitalised 
COPD exacerbations, another pre-defined goal of the 
CICERO collaboration. These novel, patient and end-user 
driven validation attempts are unique in clinical care stan-
dardisation. Finally, we limited the survey to three rounds 
a priori, where further rounds may yield further 
consensus,19 although in current practice a minimum of 3 
rounds are commonly recommended.22 The statistical 
approaches used to define consensus and dissensus, and 
the use of the Wilcoxon signed rank test could have falsely 
shown stability. However, very few elements failed to 
achieve stability of either consensus or dissensus after 3 
rounds.
In conclusion, we have developed an expert consensus 
tool through a pre-defined Delphi process, that recom-
mends which measures should be undertaken as part of 
standardisation of routine clinical care. To improve COPD 
clinical care, the respiratory field should move beyond the 
status quo from a position of limited standardisation. 
Adoption of this expert consensus will provide the first 
starting point to do this for patients hospitalised for 
exacerbations of COPD.
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